西那卡西酮对透析患者血清磷、钙和 PTH 水平的影响；系统综述与荟萃分析

IF 0.2 Q4 UROLOGY & NEPHROLOGY

Journal of Renal Injury Prevention Pub Date : 2024-01-13 DOI:10.34172/jrip.2024.32235

Mehdi Yarahmadi, M. Moonesan

{"title":"西那卡西酮对透析患者血清磷、钙和 PTH 水平的影响；系统综述与荟萃分析","authors":"Mehdi Yarahmadi, M. Moonesan","doi":"10.34172/jrip.2024.32235","DOIUrl":null,"url":null,"abstract":"Introduction: Cinacalcet is a medication prescribed to manage hypercalcemia and hyperparathyroidism in patients with chronic kidney diseases. The present study aims to evaluate the impact of cinacalcet on serum levels of calcium, phosphorus, and parathyroid hormone (PTH) in patients undergoing dialysis using a systematic review and meta-analysis approach. Materials and Methods: This study was conducted based on the PRISMA guidelines. A literature search without time restriction was performed on international databases, including Cochrane, Web of Science, Scopus, and PubMed. Data were analyzed using STATA 14 software at a significance level of P<0.05 for all tests. Results: The present meta-analysis involved twelve studies with a sample size of 1131 patients. A reduction was noted in the serum levels of calcium [SMD: -1.32 (95% CI: -2.64, -0.01)], PTH [SMD: -3.95 (95% CI: -6.53, -1.37)], phosphorus [SMD: -1.61 (95% CI: -3.01, -0.20)] and Ca×P [SMD: -5.33 (95% CI: -10.16, -0.49)] after cinacalcet use in dialysis patients. However, the variations in serum levels of alkaline phosphatase were non-significant [SMD: -0.09 (95% CI: -0.94, 0.77)]. In addition, the effectiveness of cinacalcet use on calcium serum level reduction in dialysis patients was verified at a daily dose of 30-60 mg [SMD: -0.83 (95% CI: -1.25, -0.42)] and consumption duration of 24 months [SMD: -1.26 (95% CI: -1.66, -0.87)]. Conclusion: The administration of cinacalcet significantly decreased the serum calcium, phosphorous, PTH, and Ca×P product in dialysis patients. The lowest and highest effects of cinacalcet were found for calcium and Ca×P products, respectively. The prescription of this drug appears more effective in improving hypercalcemia in dialysis patients. Registration: This investigation has been conducted in accordance with the PRISMA checklist, and its protocol was registered on the PROSPERO platform (ID: CRD42023428774).","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The impact of cinacalcet on the serum phosphorus, calcium and PTH levels in dialysis patients; a systematic review and meta-analysis\",\"authors\":\"Mehdi Yarahmadi, M. Moonesan\",\"doi\":\"10.34172/jrip.2024.32235\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Cinacalcet is a medication prescribed to manage hypercalcemia and hyperparathyroidism in patients with chronic kidney diseases. The present study aims to evaluate the impact of cinacalcet on serum levels of calcium, phosphorus, and parathyroid hormone (PTH) in patients undergoing dialysis using a systematic review and meta-analysis approach. Materials and Methods: This study was conducted based on the PRISMA guidelines. A literature search without time restriction was performed on international databases, including Cochrane, Web of Science, Scopus, and PubMed. Data were analyzed using STATA 14 software at a significance level of P<0.05 for all tests. Results: The present meta-analysis involved twelve studies with a sample size of 1131 patients. A reduction was noted in the serum levels of calcium [SMD: -1.32 (95% CI: -2.64, -0.01)], PTH [SMD: -3.95 (95% CI: -6.53, -1.37)], phosphorus [SMD: -1.61 (95% CI: -3.01, -0.20)] and Ca×P [SMD: -5.33 (95% CI: -10.16, -0.49)] after cinacalcet use in dialysis patients. However, the variations in serum levels of alkaline phosphatase were non-significant [SMD: -0.09 (95% CI: -0.94, 0.77)]. In addition, the effectiveness of cinacalcet use on calcium serum level reduction in dialysis patients was verified at a daily dose of 30-60 mg [SMD: -0.83 (95% CI: -1.25, -0.42)] and consumption duration of 24 months [SMD: -1.26 (95% CI: -1.66, -0.87)]. Conclusion: The administration of cinacalcet significantly decreased the serum calcium, phosphorous, PTH, and Ca×P product in dialysis patients. The lowest and highest effects of cinacalcet were found for calcium and Ca×P products, respectively. The prescription of this drug appears more effective in improving hypercalcemia in dialysis patients. Registration: This investigation has been conducted in accordance with the PRISMA checklist, and its protocol was registered on the PROSPERO platform (ID: CRD42023428774).\",\"PeriodicalId\":16950,\"journal\":{\"name\":\"Journal of Renal Injury Prevention\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2024-01-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Renal Injury Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.34172/jrip.2024.32235\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2024.32235","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

简介西那卡塞是一种用于控制慢性肾病患者高钙血症和甲状旁腺功能亢进的药物。本研究旨在采用系统回顾和荟萃分析方法，评估西那卡西酮对透析患者血清钙、磷和甲状旁腺激素（PTH）水平的影响。材料与方法：本研究根据 PRISMA 指南进行。在 Cochrane、Web of Science、Scopus 和 PubMed 等国际数据库中进行了无时间限制的文献检索。使用 STATA 14 软件对数据进行分析，所有检验的显著性水平均为 P<0.05。结果本荟萃分析涉及 12 项研究，样本量为 1131 例患者。透析患者使用西那卡西酮后，血清中钙[SMD：-1.32（95% CI：-2.64，-0.01）]、PTH[SMD：-3.95（95% CI：-6.53，-1.37）]、磷[SMD：-1.61（95% CI：-3.01，-0.20）]和Ca×P[SMD：-5.33（95% CI：-10.16，-0.49）]水平均有所下降。然而，碱性磷酸酶血清水平的变化并不显著[SMD：-0.09（95% CI：-0.94，0.77）]。此外，在每日剂量为 30-60 毫克[SMD：-0.83 (95% CI：-1.25, -0.42)]、用药时间为 24 个月[SMD：-1.26 (95% CI：-1.66, -0.87)]的情况下，西那卡西酮对降低透析患者血清钙水平的有效性得到了验证。结论服用西那卡西酮可显著降低透析患者的血清钙、磷、PTH 和 Ca×P 乘积。西那卡西酮对血钙和 Ca×P 乘积的作用分别最低和最高。处方这种药物似乎对改善透析患者的高钙血症更有效。注册：本研究按照 PRISMA 核对表进行，研究方案已在 PROSPERO 平台注册（ID：CRD42023428774）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The impact of cinacalcet on the serum phosphorus, calcium and PTH levels in dialysis patients; a systematic review and meta-analysis

Introduction: Cinacalcet is a medication prescribed to manage hypercalcemia and hyperparathyroidism in patients with chronic kidney diseases. The present study aims to evaluate the impact of cinacalcet on serum levels of calcium, phosphorus, and parathyroid hormone (PTH) in patients undergoing dialysis using a systematic review and meta-analysis approach. Materials and Methods: This study was conducted based on the PRISMA guidelines. A literature search without time restriction was performed on international databases, including Cochrane, Web of Science, Scopus, and PubMed. Data were analyzed using STATA 14 software at a significance level of P<0.05 for all tests. Results: The present meta-analysis involved twelve studies with a sample size of 1131 patients. A reduction was noted in the serum levels of calcium [SMD: -1.32 (95% CI: -2.64, -0.01)], PTH [SMD: -3.95 (95% CI: -6.53, -1.37)], phosphorus [SMD: -1.61 (95% CI: -3.01, -0.20)] and Ca×P [SMD: -5.33 (95% CI: -10.16, -0.49)] after cinacalcet use in dialysis patients. However, the variations in serum levels of alkaline phosphatase were non-significant [SMD: -0.09 (95% CI: -0.94, 0.77)]. In addition, the effectiveness of cinacalcet use on calcium serum level reduction in dialysis patients was verified at a daily dose of 30-60 mg [SMD: -0.83 (95% CI: -1.25, -0.42)] and consumption duration of 24 months [SMD: -1.26 (95% CI: -1.66, -0.87)]. Conclusion: The administration of cinacalcet significantly decreased the serum calcium, phosphorous, PTH, and Ca×P product in dialysis patients. The lowest and highest effects of cinacalcet were found for calcium and Ca×P products, respectively. The prescription of this drug appears more effective in improving hypercalcemia in dialysis patients. Registration: This investigation has been conducted in accordance with the PRISMA checklist, and its protocol was registered on the PROSPERO platform (ID: CRD42023428774).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Renal Injury Prevention UROLOGY & NEPHROLOGY-

CiteScore

1.60

自引率

0.00%

发文量

期刊介绍： The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.